- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01316042
Metformin for the Treatment of Premature Pubarche in Girls
April 7, 2016 updated by: Richard S. Legro, M.D., Milton S. Hershey Medical Center
A Double Blind Randomized Controlled 12 Month Trial of Metformin for the Treatment of Premature Pubarche in Girls
The primary objective of this study is to determine the safety and efficacy of metformin in lowering serum DHEAS levels in girls with premature pubarche and secondary, to observe changes in hormones associated with pubertal development including gonadotropins, sex steroids, insulin, adipocytokines, and growth factors.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children, Indiana University School of Medicine
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Hershey Medical Center
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh at the University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Girls aged 4-10 with pubic hair prior to 8 years of age
- Elevated DHEAS level above age normal levels
- Informed consent from parents and assent from the girl
Exclusion Criteria:
- Diagnosis of incomplete precocious puberty, peripheral precocious puberty, or evidence of any abnormal pituitary, hypothalamic, adrenal, thyroid, and gonadal function other than premature secretion of adrenal androgens.
- Chronic illness requiring treatment that may interfere with growth and development, i.e. chronic steroid use, renal failure, etc.
- 21-hydroxylase deficiency or other enzyme deficiency leading to the phenotype of congenital adrenal hyperplasia. 21-hydroxylase deficiency will be excluded in all patients by a fasting 17-hydroxyprogesterone (17-OHP) level < 2 ng/mL. In the case of elevated fasting 17-OHP levels, an ACTH stimulation test will be performed. A 1-hour stimulated value > 10 ng/mL will be an exclusion 82. As 21 hydroxylase deficiency is a congenital condition, any normal level in the past of 17-hydroxyprogesterone allows entry into this study.
- Uncorrected thyroid disease (defined as TSH < 0.2 mIU/ML or > 5.5 mIU/mL). A normal level within the last year is adequate for entry.
- Type I or Type II diabetes (defined as a fasting serum glucose > 125mg/dL on two occasions 83), or patients receiving anti-diabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas; patients currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
- Liver disease defined as AST or ALT > 2 times normal or total bilirubin > 2.5 mg/dL.
- Renal disease defined as BUN > 30 mg/dL or serum creatinine > 1.4 mg/dL.
- Significant anemia (Hemoglobin < 10 mg/dL).
- History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
- Known heart disease (New York Heart Association Class II or higher).
- Enrolled simultaneously into other investigative studies that require medications, proscribe the study medications, or otherwise prevent compliance with the protocol. Patients who anticipate taking longer than a one month break during the protocol should not be enrolled.
- Concomitant use other medications known to affect reproductive function or metabolism. These medications include growth hormone, IGF-1, medroxyprogesterone acetate, oral contraceptives, GnRH agonists and antagonists, anti-androgens, gonadotropins, anti-obesity drugs, somatostatin, diazoxide, ACE inhibitors, and calcium channel blockers. The washout period on all these medications will be three months.
- Suspected adrenal or ovarian tumor secreting androgens or other ectopic steroid secreting tumor.
- Suspected Cushing's syndrome.
- Lactose intolerance (the placebo filler is lactose).
- Known hypersensitivity to study medication, including ACTH and GnRH, or their excipients.
- Any concomitant medical condition that in the opinion of the investigator, may expose a subject to unacceptable level of safety risk, or that affects subject compliance.
- Subjects who anticipate having any surgery associated with restricted intake of fluids or radiological studies with contrast dye during the study period.
- Any concomitant medical condition that in the opinion of the investigator, may expose a subject to unacceptable level of safety risk, or that affects subject compliance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: sugar pill
2 pills per day for 12 months
|
2 pills per day for 12 months
|
Active Comparator: Metformin
2 212.5mg pill/day for 12 months
|
2 212.5mg pills/day for 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Serum DHEAS Levels
Time Frame: 1 year
|
Change in DHEAS level was constructed per subject as the 1-year measurement minus the baseline measurement.
Only descriptive statistics are provided, statistical tests were not conducted given the extremely small sample size per group.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard S Legro, MD, Milton S. Hershey Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
March 15, 2011
First Submitted That Met QC Criteria
March 15, 2011
First Posted (Estimate)
March 16, 2011
Study Record Updates
Last Update Posted (Estimate)
May 12, 2016
Last Update Submitted That Met QC Criteria
April 7, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35865
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Pubarche
-
Ascendance BiomedicalCompletedInfertility | Menopause | Menopause, Premature | Infertility, Female | Premature Ovarian Failure | Menopause Related Conditions | Perimenopausal Disorder | Infertility Unexplained | Menopause Premature Symptomatic | Menopause Premature Asymptomatic | Premature Ovarian Failure, Familial | Premature Ovarian Failure... and other conditionsUnited States
-
Forever Young d.o.o.Medigroup Health System, Jevremova hospital; Saint James Hospital Malta; Re-medika...UnknownMenopause | Menopause, Premature | Premature Ovarian Failure | Ovarian Failure, Premature | Ovarian Failure | Ovarian Insufficiency | Ovarian Insufficiency, Primary | Premature Ovarian Failure 2A | Premature Ovarian Failure 3 | Premature Ovarian Failure 4 | Premature Ovarian Failure 1 | Premature Ovarian Failure... and other conditionsMalta, North Macedonia, Serbia
-
GlaxoSmithKlineCompletedObstetric Labour, Premature | Premature LaborUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownPremature LabourFrance
-
Assiut UniversityNot yet recruitingPremature Rupture of Membrane
-
Cairo UniversityCompletedPremature Rupture of MembraneEgypt
-
University of OklahomaIndiana University School of MedicineCompletedPreterm Premature Rupture of Membranes
-
Centre Hospitalier Universitaire, AmiensCompletedPremature InfantFrance
-
Marmara UniversityCompleted
-
University Hospital, LimogesCompleted
Clinical Trials on sugar pill
-
Massachusetts General HospitalGaneden Biotech, Inc.TerminatedIrritable Bowel Syndrome | Major Depressive DisorderUnited States
-
Harvard University Faculty of MedicineBeth Israel Deaconess Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Hospital de Clinicas de Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompletedPeriampullary Carcinoma NosBrazil
-
GlaxoSmithKlineCompletedHealthy Subjects | Infections, BacterialAustralia
-
USDA Grand Forks Human Nutrition Research CenterCompletedInsomnia | Nutritional DeficiencyUnited States
-
Neurotune AGCross Research S.A.; Triclinium clinical trial project managment LTDCompletedNeuropathy | AIDSSouth Africa
-
Vantia LtdVeeda Clinical ResearchCompleted
-
University of California, Los AngelesCompletedAutism Spectrum DisorderUnited States
-
University of California, Los AngelesCompleted
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed